Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. (COR) President & CEO and director Robert P. Mauch reported routine equity transactions. On 11/18/2025, he exercised a non-qualified stock option to acquire 3,763 shares of common stock at an exercise price of $86.09 per share. On the same date, he sold 5,096 shares of common stock at a price of $366.64 per share under a pre-arranged Rule 10b5-1 trading plan adopted on 11/15/2024.
After these transactions, Mauch directly beneficially owned 65,746 shares of Cencora common stock and held 11,288 derivative securities in the form of stock options. The option exercised on 11/18/2025 related to a grant that became exercisable in four equal installments on 11/13/2020, 11/13/2021, 11/13/2022 and 11/13/2023.
COR reports that an affiliate intends to sell 5,096 shares of its common stock on the NYSE through Fidelity Brokerage Services LLC. The planned sale has an aggregate market value of 1,868,397.44, compared with 193,877,881 common shares outstanding.
The shares to be sold come from 1,333 shares acquired on 11/08/2024 via restricted stock vesting as compensation and 3,763 shares acquired on 11/18/2025 from an option granted on 11/13/2019 and paid for in cash. The seller, identified as Robert P. Mauch, has sold additional common shares during the past three months: 4,968 shares on 08/18/2025 for gross proceeds of 1,458,257.04; 5,097 shares on 09/18/2025 for 1,478,130.00; and 5,097 shares on 10/20/2025 for 1,665,699.60.
COR reported a planned stock sale under Rule 144 by shareholder Steven Collis. The notice covers the proposed sale of 31,349 common shares through Fidelity Brokerage Services on the NYSE, with an indicated aggregate market value of 11,493,797.36. The filing states that there were 193,877,881 common shares outstanding when the notice was prepared.
The shares to be sold come from 2,000 shares acquired via restricted stock vesting on 09/30/2023 and 29,349 shares acquired on 11/18/2025 through an option originally granted on 11/13/2019 and paid for in cash. Over the past three months, the same shareholder has sold additional common shares in several transactions, including 14,579 shares on 08/19/2025, 31,350 shares on 09/16/2025, 31,350 shares on 10/21/2025, and 50,000 shares on 11/06/2025, with gross proceeds disclosed for each sale.
Cencora (COR) reported insider equity activity by President & CEO and Director Robert P. Mauch. On 11/13/2025, he acquired 42,944 common shares at $0 upon satisfaction of performance share unit criteria, then had 18,677 shares withheld at $312.53 to cover taxes, resulting in 67,079 shares directly owned after these transactions. Separately, on 11/12/2025, he received a grant of 15,960 RSUs that vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
Cencora (COR) reported insider activity by CFO James F. Cleary. On 11/13/2025, he acquired 30,062 shares of common stock at $0 upon satisfaction of performance share unit criteria, and 13,901 shares were withheld at $312.53 to satisfy tax obligations tied to that vesting. Following these transactions, he directly held 133,889.3479 shares.
Separately, on 11/12/2025, Cleary was granted 4,733 restricted stock units for no consideration. These RSUs vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
Cencora (COR) reported an insider equity award. EVP, Chief Data & Info Officer Pawan Verma filed a Form 4 for a grant of 3,963 restricted stock units (RSUs) on 11/12/2025.
The RSUs were received for no consideration and vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028. Each RSU corresponds to one share of Cencora common stock, and the filing lists 3,963 derivative securities beneficially owned Direct (D) following the transaction.
Cencora (COR) Executive Vice President Elizabeth S. Campbell filed a Form 4 disclosing equity changes. On 11/13/2025, she acquired 20,613 shares of common stock at $0 upon performance share unit vesting, and a same‑day withholding transaction covered taxes for 9,532 shares at $312.53.
Separately, on 11/12/2025 she received a grant of 3,523 RSUs that vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028. Following these transactions, she beneficially owned 26,388.141 shares, held directly.
Cencora, Inc. (COR)
In a separate equity grant, on 11/12/2025 the officer received 2,271 Restricted Stock Units at $0. These RSUs vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
Cencora, Inc. (COR) reported insider equity changes for Executive Vice President Silvana Battaglia. On 11/13/2025, she acquired 12,885 shares of common stock at $0 upon the satisfaction of performance criteria tied to prior performance share units, and disposed of 5,612 shares at $312.53 to satisfy tax withholding related to that vesting. Following these transactions, she beneficially owns 19,947.464 common shares, held directly.
Separately, on 11/12/2025, she received a grant of 2,202 Restricted Stock Units at $0, which vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
Cencora, Inc. (COR) reported insider activity by Executive Vice President Silvana Battaglia on 11/07/2025. Two restricted stock unit (RSU) tranches vested and were settled into common stock (codes M) for 1,265 shares and 1,084 shares. To cover tax withholding, she had broker-assisted sales (code F) of 551 shares and 473 shares at $360.70 per share. After these transactions, she directly owned 12,674.464 common shares.
The footnotes state the first RSU grant vested in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025, and the second RSU grant vests on 11/08/2024, 11/08/2025, and 11/08/2026. The 2023 grant is fully settled; 1,085 RSUs from the 2024 grant remain outstanding.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
